Document Detail


Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival.
MedLine Citation:
PMID:  22354845     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: An observational prospective nonblinded clinical trial was performed to determine the effect of a drug-induced apoptosis assay results on treatments planned by oncologists. METHODS: Purified cancer cells from patient biopsies were placed into the MiCK (Microculture Kinetic) assay, a short-term culture, which determined the effects of single drugs or combinations of drugs on tumor cell apoptosis. An oncologist received the assay results before finalizing the treatment plan. Use of the MiCK assay was evaluated and correlated with patient outcomes. RESULTS: Forty-four patients with successful MiCK assays from breast cancer (n = 16), nonsmall cell lung cancer (n = 6), non-Hodgkin lymphoma (n = 4), and others were evaluated. Four patients received adjuvant chemotherapy after MiCK, and 40 received palliative chemotherapy with a median line of therapy of 2. Oncologists used the MiCK assay to determine chemotherapy (users) in 28 (64%) and did not (nonusers) in 16 patients (36%). In users receiving palliative chemotherapy, complete plus partial response rate was 44%, compared with 6.7% in nonusers (P < .02). The median overall survival was 10.1 months in users versus 4.1 months in nonusers (P = .02). Relapse-free interval was 8.6 months in users versus 4.0 months in nonusers (P < .01). CONCLUSIONS: MiCK assay results are frequently used by oncologists. Outcomes appear to be statistically superior when oncologists use chemotherapy based on MiCK assay results compared with when they do not use the assay results. When available to oncologists, MiCK assay results help to determine patient treatment plans. Cancer 2012;. © 2012 American Cancer Society.
Authors:
Linda D Bosserman; Swapnil P Rajurkar; Karl Rogers; Dirk C Davidson; Michael Chernick; Allan Hallquist; Debbee Malouf; Cary A Presant
Related Documents :
6699925 - Sonographic evaluation of pediatric rhabdomyosarcomas.
22306125 - Association between class iii β-tubulin expression and response to paclitaxel/vinorebi...
22840355 - Prognostic factors and treatment options for paediatric ependymomas.
22919385 - Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients r...
22367655 - Computational prediction of state anxiety in asian patients with cancer susceptible to ...
22235405 - Systemic taxotere chemotherapy for metastatic tumor pleurisy in cats with spontaneous b...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-21
Journal Detail:
Title:  Cancer     Volume:  -     ISSN:  1097-0142     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 American Cancer Society.
Affiliation:
Wilshire Oncology Medical Group-US Oncology, La Verne, California. Linda.bosserman@womgi.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of nobile...
Next Document:  Electrochemistry: An Efficient Way to Chemically Modify Individual Monolayers of Graphene.